Pozelimab
- Generic Name
- Pozelimab
- Brand Names
- Veopoz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2096328-94-6
- Unique Ingredient Identifier
- 0JJ21K6L2I
- Background
CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.. Under normal circ...
- Indication
Pozelimab is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
- Associated Conditions
- CHAPLE disease
- Associated Therapies
- -
Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04811716
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
π²πΎHospital Sibu, Sibu, Sarawak, Malaysia
π°π·Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04601844
- Locations
- π§πͺ
Regeneron Research Site, Antwerp, Belgium
Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04491838
- Locations
- π§πͺ
Regeneron Study Site, Antwerpen, Belgium
Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT04209634
- Locations
- πΉπ·
Regeneron Research Site, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.